natgillin/translations-raw huggingface dataset:
Dapagliflozin: A meta-analysis of cardiovascular events in the clinical program was performed. 
Dapagliflozin: Izvedli so metaanalizo srčno-žilnih dogodkov v kliničnem programu.
The two active substances in Qtern work in different ways to help control the level of sugar in your blood and remove excess sugar from your body via your urine. 
Učinkovini v zdravilu Qtern delujeta na različna načina in tako pomagata uravnati koncentracijo krvnega sladkorja in odstraniti odvečni sladkor iz telesa z urinom.
• Prior to initiation of this medicinal product and at least yearly, thereafter (see sections 4.2, 4.8, 5.1 and 5.2). 
• Pred uvedbo tega zdravila in vsaj enkrat na leto po uvedbi (glejte poglavja 4.2, 4.8, 5.1 in 5.2).
If you forget to take Qtern 
Če ste pozabili vzeti zdravilo Qtern
Dapagliflozin may add to the diuretic effect of thiazide and loop diuretics and may increase the risk of dehydration and hypotension (see section 4.4). 
Dapagliflozin lahko poveča učinek tiazidnih diuretikov in diuretikov zanke in lahko poveča tveganje za dehidracijo in hipotenzijo (glejte poglavje 4.4).
The most commonly reported adverse reaction related to renal function was serum creatinine increases, the majority of which were transient and reversible (see section 4.8). 
Najpogostejši neželeni učinek, povezan z delovanjem ledvic, je bilo zvišanje kreatinina v serumu; večinoma je bilo prehodno in reverzibilno (glejte poglavje 4.8).
Events related to decreased renal function 
Učinki, povezani z zmanjšanim delovanjem ledvic
Mean absolute lymphocyte counts remained stable with daily dosing up to 102 weeks in duration. 
Povprečno absolutno število limfocitov je ostalo med 102 tedna trajajočo vsakodnevno uporabo stabilno.
Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency, or glucose-galactose malabsorption should not take this medicinal product. 
Bolniki z redkimi prirojenimi motnjami, kot so galaktozna intoleranca, laponska oblika zmanjšane aktivnosti laktaze ali malabsorbcija glukoze-galaktoze, ne smejo jemati tega zdravila.
Polyuria includes the following preferred terms: polyuria, and pollakiuria. 
Poliurija vključuje naslednje prednostne izraze: poliurija in polakisurija.
Change from baseline (adjusted mean (95 % Confidence interval [CI]) 
Sprememba od izhodišča (prilagojeno povprečje (95 % interval zaupanja [IZ])
Qtern can be administered with or without food. 
Zdravilo Qtern se lahko jemlje s hrano ali brez nje.
In the clinical program, 34.4% of subjects had a history of cardiovascular disease (excluding hypertension) at baseline and 67.9% had hypertension. 
V kliničnem programu je izhodiščno imelo anamnezo srčno-žilne bolezni (izključujoč hipertenzijo) 34,4 % preiskovancev; hipertenzijo jih je imelo 67,9 %.
Dapagliflozin: There were no clinically relevant differences in systemic exposures between White, Black or Asian races. 
Dapagliflozin: Sistemska izpostavljenost se med belo, črno in azijsko raso ni klinično pomembno razlikovala.
The recommended dose is one 5 mg saxagliptin/10 mg dapagliflozin tablet once daily (see sections 4.5 and 4.8). 
Priporočeni odmerek je ena tableta s 5 mg saksagliptina in 10 mg dapagliflozina enkrat na dan (glejte poglavji 4.5 in 4.8).
To control your diabetes, you still need to keep to diet and exercise, even when you are taking this medicine. 
Za obvladovanje sladkorne bolezni morate upoštevati dieto in biti telesno dejavni, tudi če jemljete to zdravilo.
These symptoms could be a sign of “diabetic ketoacidosis” - a rare but serious, sometimes life-threatening problem you can get with diabetes because of increased levels of “ketone bodies” in your urine or blood, seen in tests. 
Ti simptomi so lahko znak "diabetične ketoacidoze" - redke, vendar resne, včasih smrtno nevarne motnje, ki se lahko pojavi pri sladkorni bolezni zaradi zvišane ravni "ketonskih teles" v urinu ali krvi; pokaže se na laboratorijskih preiskavah.
Compilation of reported adverse reactions for Qtern 
Strnjen prikaz poročanih neželenih učinkov zdravila Qtern
- if you have moderate or severe liver problem. 
- če imate zmerne ali hude težave z jetri.
Therefore, in keeping with routine care of the diabetic patient, monitoring for skin disorders, such as blistering, ulceration or rash, is recommended. 
Zato je v skladu z rutinsko oskrbo sladkornega bolnika priporočljivo spremljanje kožnih sprememb, kot so mehurji, razjede ali izpuščaj.
Administration of Qtern with a high-fat meal decreases dapagliflozin Cmax by up to 35 % and prolongs Tmax by approximately 1.5 hours, but does not alter AUC as compared with the fasted state. 
Uporaba zdravila Qtern z zelo mastnim obrokom zniža Cmax dapagliflozina za do 35 % in podaljša tmax za približno 1,5 ure, ne spremeni pa AUC v primerjavi s stanjem na tešče.
The same recommendations for monitoring of renal function apply to elderly patients as to all patients (see sections 4.2, 4.4, 4.8, and 5.1). 
Glede nadzora delovanja ledvic veljajo za starejše bolnike enaka priporočila kot za vse bolnike (glejte poglavja 4.2, 4.4, 4.8 in 5.1).
During post-marketing experience with saxagliptin, including spontaneous reports and clinical trials, the following adverse reactions have been reported with the use of saxagliptin: serious hypersensitivity reactions, including anaphylactic reaction, anaphylactic shock, and angioedema. 
Iz izkušenj iz obdobja trženja saksagliptina, vključno s spontanimi poročili in kliničnimi preskušanji, so glede uporabe saksagliptina poročali o naslednjih neželenih učinkih: resnih preobčutljivostnih reakcijah, vključno z anafilaktično reakcijo, anafilaktičnim šokom in angioedemom.
Studies with dapagliflozin in rats have shown toxicity to the developing kidney in the time period corresponding to the second and third trimesters of human pregnancy (see section 5.3). 
Študije z dapagliflozinom pri podganah so pokazale toksičnost za razvijajoče se ledvice v obdobju, ki ustreza drugemu in tretjemu trimesečju nosečnosti pri človeku (glejte poglavje 5.3).
If you take more Qtern tablets than you should, talk to a doctor or go to a hospital straight away. 
Če ste vzeli večji odmerek zdravila Qtern, kot bi smeli Če ste vzeli več tablet zdravila Qtern, kot bi smeli, se morate takoj posvetovati z zdravnikom ali iti v bolnišnico.
Saxagliptin is a highly potent (Ki: 1.3 nM), selective, reversible and competitive inhibitor of DPP-4, an enzyme responsible for the breakdown of incretin hormones. 
Saksagliptin je zelo močan (Ki: 1,3 nM), selektiven, reverzibilen in kompetitiven zaviralec DPP-4, encima, odgovornega za razgradnjo inkretinskih hormonov.
Combination of a single dose of dapagliflozin 20 mg and simvastatin (a CYP3A4 substrate) resulted in a 19 % increase in AUC of simvastatin and 31 % increase in AUC of simvastatin acid. 
Kombinacija enkratnega odmerka 20 mg dapagliflozina in simvastatina (substrat CYP3A4) je povzročila 19-odstotno zvišanje AUC simvastatina in 31 % zvišanje AUC simvastatinske kisline.
D, oedema peripheral 
periferni edemi
In particular, if you are following a diabetic weight control diet, continue to follow it while you are taking Qtern. 
Še zlasti, če se držite diabetične diete za obvladovanje telesne mase, nadaljujte z dieto tudi med jemanjem zdravila Qtern.
Maximum dapagliflozin plasma concentrations (Cmax) were usually attained within 2 hours after administration in the fasted state. 
Najvišja koncentracija dapagliflozina v plazmi (Cmax) je bila po navadi dosežena v 2 urah po uporabi na tešče.
Qtern must not be used in patients who have had any serious hypersensitivity reaction to a DPP-4 inhibitor or a SGLT2 inhibitor (see section 4.3). 
Zdravila Qtern se ne sme uporabljati pri bolnikih, ki so imeli resno preobčutljivostno reakcijo na kakšen zaviralec DPP-4 ali zaviralec SGLT2 (glejte poglavje 4.3).
In patients with type 2 diabetes, administration of saxagliptin inhibited DPP-4 enzyme activity throughout a 24-hour period. 
Pri bolnikih s sladkorno boleznijo tipa 2 je uporaba saksagliptina zavrla aktivnost encima DPP-4 med celotnim 24-urnim obdobjem.
Each belongs to a group of medicines called “oral anti-diabetics”. 
Obe spadata v skupino zdravil, ki jih imenujemo peroralni antidiabetiki.
A clinically relevant effect with other inducers (e.g. carbamazepine, phenytoin, phenobarbital) is not expected. 
Klinično pomembnega učinka med uporabo z drugimi induktorji (npr. karbamazepinom, fenitoinom, fenobarbitalom) ni pričakovati.
When considering the cases of tumours occurring in the different organ systems, the relative risk associated with dapagliflozin was above 1 for some tumours (bladder, prostate, breast) and below 1 for others (e.g. blood and lymphatic, ovary, renal tract), not resulting in an overall increased tumour risk associated with dapagliflozin. 
Pri obravnavi primerov tumorjev v različnih organskih sistemih je bilo relativno tveganje z dapagliflozinom večje od 1 za nekatere tumorje (sečnega mehurja, prostate, dojke) in manjše od 1 za druge (npr. krvi in limfatičnega sistema, jajčnikov, sečil), ne da bi bilo z dapagliflozinom povezano večje celokupno tveganje za tumorje.
Initiation of this medicinal product's therapy in this population (> 75 years) is not recommended (see sections 4.2, 4.8, and 5.2). 
Uvedba tega zdravila v tej populaciji (> 75 let) ni priporočljiva (glejte poglavja 4.2, 4.8 in 5.2).
If a dose is missed and it is ≥ 12 hours until the next dose, the dose should be taken. 
Če bolnik odmerek izpusti in je do naslednjega odmerka ≥ 12 ur, naj odmerek vzame.
Actions of both medicinal products are regulated by the plasma glucose level. 
Delovanje obeh zdravil uravnava koncentracija glukoze v plazmi.
Erectile dysfunction, pruritus genital, vulvovaginal pruritus 
Motnje reprodukcije in dojk erektilna disfunkcija, genitalni pruritus, vulvovaginalni pruritus
When driving or using machines, it should be taken into account that dizziness has been reported in studies with combined use of saxagliptin and dapagliflozin. 
V primeru vožnje ali upravljanja strojev je treba upoštevati, da je bila v študijah kombinirane uporabe saksagliptina in dapagliflozina opisana omotica.
Dapagliflozin's glucuretic effect is observed after the first dose, is continuous over the 24-hour dosing interval, and is sustained for the duration of treatment. 
Glukuretični učinek dapagliflozina je opazen po prvem odmerku, je stalen v 24-urnem intervalu odmerjanja in se med obdobjem zdravljenja ohrani.
The rise in insulin from pancreatic beta-cells and the decrease in glucagon from pancreatic alpha-cells were associated with lower fasting glucose concentrations and reduced glucose excursion following an oral glucose load or a meal. 
Porast insulina iz pankreatičnih celic beta in upad glukagona iz pankreatičnih celic alfa sta bila povezani z nižjo koncentracijo glukoze na tešče in manjšim porastom glukoze po peroralni obremenitvi z glukozo ali po obroku.
Caution should be exercised in patients for whom a dapagliflozin-induced drop in blood pressure could pose a risk, such as patients with known cardiovascular disease, patients on anti-hypertensive therapy with a history of hypotension or elderly patients. 
Previdnost je potrebna pri bolnikih, za katere bi z dapagliflozinom povzročen padec krvnega tlaka lahko pomenil tveganje, npr. pri bolnikih z znano srčno-žilno boleznijo, bolnikih, ki se zdravijo z antihipertenzivi in imajo hipotenzijo v anamnezi ali pri starejših bolnikih.
The primary safety (non-inferiority) and efficacy (superiority) endpoint was a composite endpoint consisting of the time-to-first occurrence of any of the following major adverse CV events (MACE): CV death, nonfatal myocardial infarction, or nonfatal ischemic stroke. 
Primarni opazovani dogodek varnosti (neinferiornosti) in učinkovitosti (superiornosti) je bil sestavljen opazovani dogodek, ki je obsegal čas do prvega pojava katerega od naslednjih hudih neželenih srčno-žilnih učinkov (MACE - major adverse cardiac events): srčno-žilne smrti, miokardnega infarkta brez smrtnega izida ali možganske kapi brez smrtnega izida.
What Qtern looks like and contents of the pack 
Izgled zdravila Qtern in vsebina pakiranja
Urine laboratory assessments Due to its mechanism of action, patients taking Qtern will test positive for glucose in their urine. 
Zaradi mehanizma delovanja zdravila imajo bolniki, ki jemljejo zdravilo Qtern, pozitiven izvid testa za glukozo v urinu.
In a number of cases, the presentation of the condition was atypical with only moderately increased blood glucose values, below 14 mmol/litres (250 mg/dl). 
V številnih primerih je bila klinična slika te motnje neznačilna in koncentracija glukoze v krvi je bila le zmerno zvišana, pod 14 mmol/l (250 mg/dl).
Dapagliflozin: Dapagliflozin exposure increased proportional to the increment in dapagliflozin dose over the range of 0.1 to 500 mg and its pharmacokinetics did not change with time upon repeated daily dosing for up to 24 weeks. 
Dapagliflozin: Izpostavljenost dapagliflozinu se je v razponu odmerkov od 0,1 do 500 mg povečevala sorazmerno povečanju odmerka in njegova farmakokinetika se s časom med ponavljajočo se vsakodnevno uporabo v obdobju do 24 tednov ni spremenila.
Dapagliflozin and related metabolites are primarily eliminated via urinary excretion with less than 2 % as unchanged dapagliflozin. 
Dapagliflozin in sorodni presnovki se izločijo predvsem v urinu, pri čemer je manj kot 2 % nespremenjenega dapagliflozina.
Qtern 5 mg/10 mg tablets are available in aluminium blisters in pack sizes of 14, 28, or 98 film-coated tablets in calendar blisters and 30 film-coated tablets in blister. 
Tablete Qtern 5 mg/10 mg so na voljo v aluminijskih pretisnih omotih v velikostih pakiranj po 14, 28 ali 98 filmsko obloženih tablet v koledarskih pretisnih omotih in po 30 filmsko obloženih tablet v pretisnih omotih.
Dapagliflozin: The mean dapagliflozin AUCss in females was estimated to be about 22 % higher than in males. 
Dapagliflozin: Ocenjeno je, da je povprečna AUCss dapagliflozina pri ženskah približno 22 % višja kot pri moških.
Thus, changes in blood protein levels in various disease states (e.g. renal or hepatic impairment) are not expected to alter the disposition of saxagliptin. 
Zato ni pričakovati, da bi spremenjena koncentracija beljakovin v krvi pri različnih boleznih (npr. okvari ledvic ali jeter) spremenila odstranjevanje saksagliptina.
- Do not take a double dose of Qtern to make up for a forgotten dose. 
- Ne vzemite dvojnega odmerka, če ste pozabili vzeti prejšnji odmerek.
The effect on offspring body weights were noted until postnatal day 92 and 120 in females and males, respectively. 
Učinek na telesno maso mladičev je bil pri samicah opazen do 92. in pri samcih do 120. postnatalnega dneva.
The hazard ratio comparing dapagliflozin to comparator was 0.79 (95 % CI: 0.58, 1.07), indicating that in this analysis dapagliflozin is not associated with an increase in cardiovascular risk in patients with type 2 diabetes mellitus. 
Razmerje ogroženosti za dapagliflozin v primerjavi s primerjalno učinkovino je bilo 0,79 (95 % IZ: 0,58, 1,07); to kaže, da v tej analizi dapagliflozina pri bolnikih s sladkorno boleznijo tipa 2 ne spremlja večje srčno-žilno tveganje.
Treatment with Qtern resulted in change from baseline for systolic blood pressure ranging from -1.3 to -2.2 mm Hg and for diastolic blood pressure ranging from -0.5 to -1.2 mm Hg caused by Qtern's mild diuretic effect. 
Zdravljenje z zdravilom Qtern je spremenilo sistolični krvni tlak (KT) v primerjavi z izhodiščem v razponu od -1,3 do -2,2 mmHg in diastolični krvni tlak v razponu od -0,5 do -1,2 mmHg; to je posledica blagega diuretičnega učinka zdravila Qtern.
After an oral glucose load, this produced in a 2- to 3-fold increase in circulating levels glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), decreased glucagon concentrations, and increased beta-cell responsiveness, resulting in higher insulin and C-peptide concentrations. 
Po peroralni obremenitvi z glukozo je to povzročilo 2- do 3-kratno zvišanje koncentracije glukagonu podobnega peptida-1 (GLP-1 - glucagon-like peptide-1) in od glukoze odvisnega insulinotropnega polipeptida (GIP - glucose-dependent insulinotropic polypeptide) v obtoku, znižalo je koncentracijo glukagona in povečalo odzivnost celic beta, zaradi česar sta se zvišali koncentracija insulina in C-peptida.
Interference with 1,5-anhydroglucitol (1,5-AG) assay Monitoring glycaemic control with 1,5-AG assay is not recommended as measurements of 1,5-AG are unreliable in assessing glycaemic control in patients taking SGLT2 inhibitors. 
Motenje preiskave z 1,5-anhidroglucitolom (1,5-AG) Spremljanje urejenosti glikemije s preiskavo z določanjem ravni 1,5-anhidroglucitola (1,5-AG) v plazmi ni priporočeno, saj pri bolnikih, ki jemljejo zaviralce SGLT2, z merjenjem vrednosti 1,5-AG ni mogoče zanesljivo spremljati urejenosti glikemije.
Saxagliptin/dapagliflozin combination: Of the 1169 subjects treated in the pooled safety data from the 3 clinical trials, 1007 subjects (86.1 %) were aged < 65 years, 162 subjects (13.9 %) were aged ≥ 65 years, and 9 subjects (0.8 %) were aged ≥ 75 years. 
Kombinacija saksagliptina/dapagliflozina: Od 1169 zdravljenih bolnikov v kumulativnih podatkih o varnosti iz 3 kliničnih preskušanj je bilo 1007 bolnikov (86,1 %) starih < 65 let, 162 (13,9 %) ≥ 65 let in 9 (0,8 %) ≥ 75 let.
The pharmacokinetics of dapagliflozin, and saxagliptin and its major metabolite were similar in healthy subjects and in patients with type 2 diabetes. 
Farmakokinetika dapagliflozina, saksagliptina in njegovega glavnega presnovka je bila pri zdravih preiskovancih in bolnikih s sladkorno boleznijo tipa 2 podobna.
Caution should be exercised in patients with a history of pancreatitis. 
Previdnost je potrebna pri bolnikih, ki imajo v anamnezi pankreatitis.
Saxagliptin: Race was not identified as a statistically significant covariate on the apparent clearance of saxagliptin and its metabolite. 
Saksagliptin: Rasa ni bila statistično značilna sospremenljivka, kar zadeva navidezni očistek saksagliptina in njegovega presnovka.
The study population included those ≥ 65 years (n=8561) and ≥ 75 years (n=2330), with normal or mild renal impairment (n=13,916) as well as moderate (n=2240) or severe (n=336) renal impairment. 
Populacija v študiji je zajela bolnike, stare ≥ 65 let (n = 8.561) in ≥ 75 let (n = 2.330), z normalnim delovanjem ledvic ali blago okvaro ledvic (n = 13.916) kot tudi z zmerno (n = 2.240) ali hudo (n = 336) okvaro ledvic.
The Cmax and AUC values of saxagliptin and its major metabolite increased proportionally with the increment in the saxagliptin dose, and this dose-proportionality was observed in doses up to 400 mg. 
Vrednosti Cmax in AUC saksagliptina in njegovega glavnega presnovka so naraščale sorazmerno s povečevanjem odmerka saksagliptina; to sorazmernost odmerku so opažali v odmerkih do 400 mg.
Use of alternative methods to monitor glycaemic control is advised. 
Pri teh bolnikih je priporočena uporaba drugih metod za spremljanje urejenosti glikemije.
Drug interactions: 
Medsebojna delovanja z zdravili:
This medicinal product is not recommended for use in patients at risk of volume depletion (e.g. receiving loop diuretics) (see section 4.5) or who are volume depleted, e.g. due to acute illness (such as acute gastrointestinal illness with nausea, vomiting or diarrhoea). 
Tega zdravila ni priporočljivo uporabljati pri bolnikih s tveganjem za zmanjšanje volumna (npr. pri bolnikih, ki prejemajo diuretike zanke) (glejte poglavje 4.5) in bolnikih, ki imajo zmanjšan volumen, npr. zaradi akutne bolezni (kakršne so akutne bolezni prebavil z navzeo, bruhanjem ali drisko).
The major active metabolite of saxagliptin, 5-OH-saxagliptin, is also a selective, reversible, competitive DPP-4 inhibitor, half as potent as saxagliptin. 
Tudi glavni aktivni presnovek saksagliptina, 5-OH-saksagliptin, je selektiven, reverzibilen, kompetitiven zaviralec DPP-4, pol tako močan kot saksagliptin.
In post-marketing experience of saxagliptin, there have been spontaneously reported adverse reactions of acute pancreatitis. 
Med obdobjem trženja saksagliptina so spontano poročali o neželenem učinku akutnem pankreatitisu.
These medications did not alter the pharmacokinetics of dapagliflozin. 
Ta zdravila niso spremenila farmakokinetike dapagliflozina.
Treatment with SGLT2 inhibitors increases the risk for urinary tract infections. 
Zdravljenje z zaviralci SGLT2 poveča tveganje za okužbe sečil.
- if you experience rapid weight loss, feeling sick or being sick, stomach pain, excessive thirst, fast and deep breathing, confusion, unusual sleepiness or tiredness, a sweet smell to your breath, a sweet or metallic taste in your mouth, or a different odour to your urine or sweat, contact a doctor or the nearest hospital straight away. 
- če se vam pojavijo hitra izguba telesne mase, slabost ali bruhanje, bolečine v trebuhu, prekomerna žeja, hitro in globoko dihanje, zmedenost, neobičajna zaspanost ali utrujenost, sladek vonj izdihanega zraka, sladek ali kovinski okus v ustih ali spremenjen vonj urina ali znoja, se takoj posvetujte z zdravnikom ali pojdite v najbližjo bolnišnico.
Immunocompromised patients 
Imunsko oslabeli bolniki
These are signs of dehydration: - very dry or sticky mouth, feeling very thirsty - feeling very sleepy or tired - passing little or no water (urine) - fast heart beat. 
Znaki dehidracije so: - zelo suha ali lepljiva usta, občutek hude žeje - izrazita zaspanost ali utrujenost - izločanje malo ali sploh nič vode (urina) - hitro bitje srca.
While a causal relationship between dapagliflozin and bladder cancer is unlikely (see sections 4.8 and 5.3), as a precautionary measure, Qtern is not recommended for use in patients concomitantly treated with pioglitazone. 
Uporaba pri bolnikih, zdravljenih s pioglitazonom Vzročna povezava med dapagliflozinom in rakom sečnega mehurja sicer ni verjetna (glejte poglavji 4.8 in 5.3), toda iz previdnosti zdravila Qtern ni priporočljivo uporabljati pri bolnikih, ki se sočasno zdravijo s pioglitazonom.
Dapagliflozin and saxagliptin exposure is increased in patients with severe hepatic impairment (see sections 4.2 and 5.2). 
Izpostavljenost dapagliflozinu in saksagliptinu je pri bolnikih s hudo okvaro jeter večja (glejte poglavji 4.2 in 5.2).
However, subjects on saxagliptin with a history of heart failure or impaired renal function at baseline were not at an increased risk relative to placebo for the primary or secondary composite endpoints or all-cause mortality. 
Vendar pa bolniki z izhodiščno anamnezo srčnega popuščanja ali okvaro delovanja ledvic, ki so prejemali saksagliptin, v primerjavi s placebom niso imeli večjega relativnega tveganja za primarni ali sekundarni sestavljeni opazovani dogodek ali za umrljivost zaradi vseh vzrokov.
If you stop taking Qtern 
Če ste prenehali jemati zdravilo Qtern
The majority of the urinary tract infection adverse events were reported in females (81 % of subjects with UTI), were mild or moderate in intensity, of single occurrence, and most patients continued on therapy. 
O večini okužb sečil so poročali pri ženskah (81 % preiskovancev z okužbo sečil); okužbe so bile blage ali zmerne, pojavile so se le enkrat in večina bolnikov je nadaljevala zdravljenje.
These are the signs of low blood sugar: - shaking, sweating, feeling very anxious, fast heart beat - feeling hungry, headache, change in vision - a change in your mood or feeling confused. 
Znaki nizkega krvnega sladkorja so: - tresenje, znojenje, občutek hude tesnobe, hitro bitje srca - lakota, glavobol, spremembe vida - sprememba razpoloženja ali zmedenost.
Dapagliflozin: In the 13-study, short-term, placebo-controlled pool, reported terms referring to events related to decreased renal function were grouped (e.g. decreased renal creatinine clearance, renal impairment, increased blood creatinine and decreased glomerular filtration rate). 
Dapagliflozin: V kumulativni analizi 13 kratkotrajnih, s placebom kontroliranih študij so poročane izraze, ki so se nanašali na učinke, povezane z zmanjšanim delovanjem ledvic združili v skupino (npr. zmanjšan ledvični očistek kreatinina, okvara ledvic, zvišan kreatinin v krvi in zmanjšana hitrost glomerularne filtracije).